Introduction
Nuclear receptors for steroid/thyroid hormones, vitamins A and D, and fat-soluble ligands form a gene superfamily of ligandinducible transaction factors that play important roles in a wide spectrum of biological events by regulating the expressions of sets of target genes. [1] [2] [3] [4] Endogenous thyroid hormone 3,5,3′-triiodo-l-thyronine (T3) exerts significant effects on growth, development, and homeostasis in mammals.
Recently, the abilities of a number of environmental chemicals to disrupt normal endocrine homeostasis, and potentially the physiological and reproductive capacity of an organism, have gained worldwide attention. [5] [6] [7] These chemicals, so called "endocrine-disrupting chemicals" (EDCs), can mimic natural hormones in experimental animals, wildlife, and humans. Reports of increasing incidences in developmental abnormalities of the human male reproductive tract and the recent identification of various environmental chemicals with hormonal activities necessitate the screening of a larger number of compounds so as to gain an overview of EDCs. Thus, there is a great need for an effective method to screen EDCs in vitro. In recent years, the main concerns about EDCs have been estrogenic chemicals present in our environment. Several research groups have developed in vivo and in vitro screening assays for estrogen receptor activated compounds. [8] [9] [10] [11] [12] However, the endocrine system actually consists of many systems having complex interactions and interdependencies. 1, 13 To assess the essential risk to an endocrine system from specific chemicals, the evaluation of the binding affinity of the compounds for not only estrogen receptors but also for other nuclear receptors is required. While TR is especially important for several organ physiologies as mentioned above, there is no report of largescale screening of chemicals present in our environment for new ligands for the TR. Large-scale investigation of the specificity of binding ligands for TR needs a rapid, sensitive, and inexpensive high-throughput screening assay.
We have previously demonstrated a novel bioaffinity sensor based on the specific binding of estrogen to its receptor immobilized on a gold disk electrode. 14, 15 This uses the concept of "ion-channel mechanism" proposed by Sugawara et al. 16 This electrochemical screening system has advantages of being rapid, of low cost, and adaptable to high-throughput applications without sacrificing either sensitivity or selectivity. Here, we express recombinant human TR (hTR) in bacteria using a histidine-tag fusion system and modify the receptor on an Au electrode. This bioaffinity sensor is then applied to the detection and relative quantitation of hTR-active ligands.
Experimental

DNA construction and expression of histidine-tagged ligandbinding domain of hTR
Restriction enzymes were obtained from New England Biolabs (USA). T4 DNA ligase was obtained from Takara. The plasmid peA101 encoding full-length hTRβ was kindly provided by The Salk Institute for Biological Studies. All other chemicals were reagent grade obtained from commercial sources and were used without further purification.
Plasmid pEThTR-LBD, the bacterial expression vector containing the his-tag gene fused in-frame with the ligand binding region of hTR (amino acids 198-456), was cloned by PCR. Human cDNA library of Hela endocervical carcinoma cells were used as the PCR template. The primers for hTR-LBD were: 5′-GGATCCGAGCTGCAGAAGTCATC-3′ and 5′- The recombinant human thyroid hormone receptor (TR) was expressed as an in-frame fusion with ten consecutive histidine residues using a bacterial system; then the receptor was immobilized on an Au-electrode with Ni(II)-mediated chemisorption using the histidine tag and thiol-modified nitrilotriacetic acid. The receptor-modified electrode could rapidly detect ligand binding to hTR without any separation procedures, and showed a good response in a concentrationdependent manner. The sensitivity of this biosensor based on ligand-receptor interactions was comparable to those of conventional competitive ligand binding assays using radio-labeled ligands. Our results strongly suggest that our new biosensor can be applied to the identification of new ligands for hTR. 
CTCGAGCTAATCCTCGAACACTTCC-3′, that contained
BamHI and XhoI cleavage sites, respectively (restriction sites underlined). The PCR-generated 792-kb fragment was digested with BamHI and XhoI, and the resulting DNA fragment was subcloned into BamHI, XhoI-digested pET28a(+) vector (Novagen). Correct insertion of the fragment was verified by DNA sequencing. Plasmids were amplified and purified by standard techniques. The resulting vector was allowed to express in hTR-LBD in Escherichia coli BL21(DE3) cells (Novagen) using the T7 expression system. E. coli BL21(DE3)pLysS containing pEThTR-LBD were grown overnight at 37˚C in 4 ml of Luria Broth supplemented with 100 µg/ml ampicillin and 15 µg/ml chloramphenicol. After overnight growth, the cells were diluted 100-fold in fresh medium containing 100 µg/ml ampicillin and 15 µg/ml chloramphenicol, and the outgrowth was allowed to proceed to an optical density of 0.7 at 600 nm. Recombinant protein production was initiated by the addition of isopropyl thiogalactopyranoside (IPTG; Wako Pure Chemical Industries Ltd.) to a final concentration of 1 mM and incubation was continued for another 24 h at 14˚C. The cells were pelleted by centrifugation at 4˚C. The pellet was resuspended in 10 ml of lysis buffer (50 mM NaH2PO4-Na2HPO4 (pH 8.0), 25 mM β-mercaptoethanol, 0.1 mM PMSF, 300 mM NaCl, 10% glycerol). The resulting suspension was frozen at -80˚C, then thawed at 37˚C, followed by sonication on ice (45 s, 200 W). Cell fragments and insoluble material were removed by centrifugation (20 min, 20000g ) at 4˚C. Purification of the recombinant protein was performed by affinity chromatography under native conditions. The supernatant (soluble material) was loaded on a 5 ml Hitrap TM chelating column (Amersham Pharmacia Biotech). The column was washed with 20 ml of wash buffer (50 mM NaH2PO4-NaOH (pH 6.0), 300 mM NaCl, 5 mM β-mercaptoethanol, 0.1 mM PMSF, 5 mM NaMBS, 10% Glycerol) followed by 20 ml wash buffer containing 80 mM imidazole. The His-tagged hTR-LBD was eluted by wash buffer containing 500 mM imidazole. Fractions containing hTR-LBD were collected and loaded on a PD-10 desalting column. hTR-LBD was eluted by a store buffer (20 mM HEPES-KOH (pH 7.2), 500 mM KCl, 1 mM DTT, 0.1 mM PMSF, and 10% glycerol). The protein concentration was determined using the Bradford protein assay (Dojindo, Japan) with bovine serum albumin as the standard.
Cell lysate fractions, purified with hTR-LBD, were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) using 12% gel according to standard protocols. The gels were either stained with Coomassie Brilliant Blue or transferred to polyvinylidene difluoride membrane (Millipore) for Western blotting. After transfer for Western blotting, the filter was blocked and incubated with the anti-His HRP conjugate (Qiagen). The bound antibody was detected with Super Signal West Pico ® chemiluminescent reagents (Pierce) using a Night OWL ® molecular light imager (Berthold).
Electrode modification and cyclic voltammetry (CV)
Histidine-tagged hTR-LBD was immobilized onto an Au electrode via metal (Ni 2+ ) complexation, as reported previously. 17 A human estrogen receptor ligand-binding domain (hER-LBD) was synthesized and immobilized on a gold disk electrode as mentioned in our previous report. 14, 15, 17 This hER-LBD modified electrode was used as control electrode.
Cyclic and differential pulse voltammetry were performed using a Bioanalytical Systems Co. Model ALS410 potentiostat. A platinum wire and a standard Ag/AgCl (saturated KCl) electrode were used as counter and reference electrodes, respectively. T3 (>99%) was purchased from Tokyo Kasei Kogyo Co. Ltd. (Japan).
Results and Discussion
hTRs are ligand-dependent transcription factors that regulate diverse aspects of growth, development, and homeostasis by binding as heterodimers to their cognate DNA response element to modulate transcription of the target gene. Transactivation by TR involves a conserved AF-2 domain, containing the regions of ligand binding and recognition, located in the distal carboxyterminus of the receptor. [1] [2] [3] In this study, we constructed an expression vector, pEThTR-LBD, in which the ligand binding domain of hTR could be expressed in E. coli as the N terminus of an in-frame fusion with ten consecutive histidine residues.
Plasmid pEThTR-LBD was transformed into E. coli strain BL21(DE3) and the gene expression was induced by IPTG at 14˚C.
The expressed protein was purified by affinity chromatography on Ni(II)-NTA carrying resin and then analyzed by SDS-PAGE. A typical result of protein-expression and its purification is shown in Fig. 1 . The hTR-LBD with the predicted molecular weight (32 kDa) appeared only in cell extracts prepared from cells treated with IPTG (Fig. 1, lane 3) . A similar result was obtained by Western analysis using antihis-tag antibody (data not shown). The fusion protein was never observed in extracts from cells not treated with IPTG (Fig. 1, lane 2) . Affinity chromatography was carried out under native conditions. The soluble fraction of a crude lysate was loaded on a NTA-Ni(II) complex-carrying resin, and hTR-LBD containing a histidine affinity tag was effectively bound to the resin. The removal of background proteins and the elution of histidine-tagged protein from the column was achieved by the addition of 80 mM and 500 mM imidazole solutions; which compete with the tagged proteins for binding sites on the NTA resin (Fig. 1, lanes 4 -6) . In this manner, hTR-LBD was obtained as a nearly homogenous species without any breakdown products.
The concentration of the purified recombinant hTR-LBD was 12.9 mg/l-cell culture.
The recombinant hTR-LBD was immobilized on Auelectrodes with Ni(II)-mediated chemisorption using the histidine tag and thiol-modified NTA (Fig. 2) .
The immobilization of the recombinant protein was examined using cyclic voltammetry at 25 mV s -1 in sample buffer [20 mM HEPES-KOH (pH 7.4) and 100 mM KCl] containing 5 mM each of K4Fe(CN)6 and K3Fe(CN)6. The peak currents due to the reversible redox reaction of the marker ions decreased on the protein modified electrode as compared with the that of a bare one (Fig. 3 ). This peak current depression can be explained by a decrease in the local concentration of the marker ions near the electrode, mainly due to the steric barrier based on the protein modification on the electrode surface. 15, 18 The interaction between the recombinant receptor and its ligand molecules on the Au disk electrode surface were evaluated by electrochemical measurement. Figure 4 shows the cyclic voltammograms of the electrode in the absence and presence of T3, a natural ligand for hTR. The redox current was significantly suppressed by T3 in a concentration-dependent manner in the hTR-LBD modified electrode system. The electrochemical responses achieved a stable situation within 5 min. On the other hand, T3 did not influence unmodified (data not shown) and hER-LBD modified electrodes (Fig. 5) . This phenomenon, therefore, was attributed to the immobilized hTR-LBD that complexed specifically with the ligand molecule on the electrode surface and perturbed the electrical contact and electron transfer rate between the redox probe and the electrode surface. Although it is not clear how the complexation influences the amperometric transduction of the redox marker at the electrode surface, ligand-inducible conformational changes in hTR-LBD may affect this peak current depression. As shown in recent X-ray crystallographic and functional studies, 19 upon the binding of a ligand the TR changes its conformation in the ligand-binding domain that enables recruitment of co-activators, which allows the receptor to interact with the basal transcriptional machinery more efficiently and to activate transcription. [1] [2] [3] It is well known that the co-activator proteins bind to the liganded TR by hydrophobic interaction. helix 12 into the scaffold formed by helices 3, 4 and 5. 19, 20 This conformational change may be achieved on the electrode surface, and therefore it was likely that electrochemical reaction of hidrophilic redox marker was suppressed by alteration in hydrophobicity of the protein layer on the electrode surface. Figure 6 shows the relationship between the absolute values of the diminution of the anodic peak current (∆ipa) and the concentration of the compounds. The hTR-LBD-modified electrode showed a good response to the compounds over a wide range of concentrations. The sensor showed a linear response to T3 in the range of 10 -9 to 10 -6 M. The sensitivity of this electrochemical sensing system based on a ligand-receptor interaction was comparable to those of conventional methods, such as competitive binding assays using radioactive T3. On the other hand, DMSO used as a control had no significant effect on the sensor under the experimental conditions. These results suggest that the recombinant receptor immobilized on the Au electrode surface maintains its ligand-binding activity.
In conclusion, the electrochemical detection system presented here showed a good response to thyroid hormones that have long been known to play critical roles in the development in mammals. This biosensor system is based on the specific binding of thyroid hormone to its receptor immobilized on a gold disk electrode, and can evaluate its binding capacity for hTR without any separation procedures or chemical modifications. Although it is necessary to investigate into the reuse and preservation of the receptor modified electrode, our system can be used as a rapid and inexpensive high-throughput screening method for EDCs. Further, thyroid hormones have potentially useful features that include possible uses in weight reduction for the treatment of obesity, cholesterol lowering for treating hyperlipidemia, amelioration of depression and so on. 21, 22 The sensor will have uses as a tool not only in the largescale screenings of environmental compounds, but also as an effective method for screening in drug discoveries or clinical diagnoses. 
